抗血管生成药物（AAD）主要针对血管内皮生长因子-A信号通路，二十年来已成为癌症患者的治疗选择。在此期间，抗血管生成治疗取得了丰富的临床经验，开发了新的AAD，并通过单药治疗和联合治疗扩大了AAD治疗各种癌症的临床适应症。然而，仍然迫切需要改善临床可用 AAD 的治疗效果并开发更有效的下一代 AAD。这篇综述旨在提供肿瘤血管生成的历史和透视观点，让读者获得机制见解并了解新的治疗发展。我们回顾了概念发起和 AAD 发现的历史，并总结了该领域抗血管生成癌症治疗的最新临床转化。版权所有 © 2024 中华医学会，由 Wolters Kluwer, Inc. 制作，CC- BY-NC-ND 许可证。

Anti-angiogenic drugs (AADs), which mainly target the vascular endothelial growth factor-A signaling pathway, have become a therapeutic option for cancer patients for two decades. During this period, tremendous clinical experience of anti-angiogenic therapy has been acquired, new AADs have been developed, and the clinical indications for AAD treatment of various cancers have been expanded using monotherapy and combination therapy. However, improvements in the therapeutic outcomes of clinically available AADs and the development of more effective next-generation AADs are still urgently required. This review aims to provide historical and perspective views on tumor angiogenesis to allow readers to gain mechanistic insights and learn new therapeutic development. We revisit the history of concept initiation and AAD discovery, and summarize the up-to-date clinical translation of anti-angiogenic cancer therapy in this field.Copyright © 2024 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.